<DOC>
	<DOCNO>NCT02561091</DOCNO>
	<brief_summary>The purpose research study test effectiveness safety study drug , AM-111 . AM-111 test treatment sudden sensorineural hearing loss cause unknown .</brief_summary>
	<brief_title>AM-111 Treatment Acute Inner Ear Hearing Loss</brief_title>
	<detailed_description>This phase III study assess drug 's safety aim demonstrate efficacy intratympanic AM-111 injection treatment severe profound idiopathic sudden sensorineural hearing loss ( ISSNHL ) . The active pharmaceutical ingredient AM-111 JNK inhibitor ( D-JNKI-1 ) , synthetic peptide consist 31 D-amino acid , act c-Jun N-terminal kinase ( JNK ) ligand .</detailed_description>
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Hearing Loss , Sensorineural</mesh_term>
	<criteria>1 . Unilateral ISSNHL onset within 72 hour prior study treatment ; 2 . Mean hearing threshold equal worse ( ≥ ) 60 dB average across 3 affect contiguous air conduction audiometric pure tone frequency ( `` pure tone average '' , PTA ) ; * 3 . Mean hearing loss equal worse ( ≥ ) 40 dB average across air conduct PTA frequency compare unaffected contralateral ear reference value preexist audiogram ISO 7029 ; 2000 norm value case asymmetric hearing prior ISSNHL incident ; 4 . Age ≥ 18 ≤ 65 year day screening ; Other protocoldefined inclusion criterion may apply . 1 . Bilateral ISSNHL ; 2 . Acute hearing loss noise trauma , barotrauma head trauma ; 3 . History autoimmune hearing loss , radiationinduced hearing loss , endolymphatic hydrops Menière 's disease affect ear ; 4 . History chronic inflammatory suppurative ear disease cholesteatoma affect ear ; 5 . History acoustic neuroma retrocochlear damage affect ear ; 6 . History otosclerosis affect ear ; 7 . Suspected perilymph fistula membrane rupture affect ear ; 8 . Congenital hearing loss ; 9 . History ISSNHL past 2 year ; 10 . Otitis medium otitis externa ongoing end within 7 day prior study treatment ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Deafness</keyword>
	<keyword>Hearing Loss , Sensorineural</keyword>
	<keyword>Ear Diseases</keyword>
	<keyword>Hearing Disorders</keyword>
	<keyword>Otorhinolaryngologic Diseases</keyword>
	<keyword>Sensation Disorders</keyword>
	<keyword>Signs Symptoms</keyword>
	<keyword>Hearing Speech impairment</keyword>
	<keyword>Hearing Loss , Unilateral</keyword>
</DOC>